Lucid Diagnostics announces proposed public stock offering

Lucid Diagnostics Inc. (NASDAQ: LUCD) announced its intention to offer shares of common stock through an underwritten public offering. The cancer prevention medical diagnostics company plans to grant underwriters a 30-day option to purchase additional shares.

The company stated proceeds from the offering are expected to support working capital and general corporate purposes. Completion of the offering remains subject to market conditions, with no assurance regarding timing, size, or terms.

Canaccord Genuity LLC and BTIG, LLC are serving as joint bookrunners for the offering, while Maxim Group LLC acts as co-manager.

The offering is being made pursuant to a shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission on December 6, 2022. A prospectus supplement relating to the offering will be filed with the SEC.

Lucid Diagnostics is a subsidiary of PAVmed Inc. (NASDAQ: PAVM) and focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer. The company markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer.

You May Also Be Interested In

• Banzai launches $1M public offering of Class A common stock
• Nu-Med Plus acquires Avid Gold, targets Canadian gold properties
• FDA clears Merck's Keytruda combo for muscle-invasive bladder cancer